•   
  •   

World AstraZeneca - Corona vaccine in study encouraging

12:15  26 october  2020
12:15  26 october  2020 Source:   de.reuters.com

Pfizer CEO makes it clear: Covid-19 vaccine will not come until the end of November - and thus not as announced by Donald Trump before the election

 Pfizer CEO makes it clear: Covid-19 vaccine will not come until the end of November - and thus not as announced by Donald Trump before the election Joe Biden clearly leads in almost all surveys, there is still no clear trend reversal in the Corona- Pandemic in sight, and then there's Donald Trump's recent Covid-19 illness. The chances of the current US president being re-elected are not looking too rosy. An approved vaccine against the novel coronavirus before the US election on November 3, 2020 could possibly change something. Donald Trump had announced early on that approval of a vaccine before this point in time was very likely.

AstraZeneca , which developed its vaccine in conjunction with the University of Oxford, had planned to conduct trials in Peru. China’s Sinopharm is already undertaking tests Martos said that a study had found that 35 percent of the population have Covid antibodies, meaning they had already been infected.

Because of safety concerns, AstraZeneca paused late-stage trials of its coronavirus vaccine , which is being tested in locations like São Paolo, Brazil.Credit Amanda Perobelli/Reuters.

Frankfurt (Reuters) - The potential corona vaccine from the British pharmaceutical company AstraZeneca has achieved promising results in clinical development.

FILE PHOTO: A test tube labelled with the vaccine is seen in front of AstraZeneca logo in this illustration taken © Reuters / DADO RUVIC FILE PHOTO: A test tube labeled with the vaccine is seen in front of AstraZeneca logo taken in this illustration

In older people, the group with the highest risk of severe disease, a "robust immune response" arose, reported the "Financial Times" on Monday, citing two people familiar with the matter. The vaccine, which AstraZeneca is developing together with Oxford University, has triggered protective antibodies and T cells in the elderly. These results mirrored data published in July showing that the vaccine elicited a "robust immune response" in healthy adults between the ages of 18 and 55.

Exclusive: AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this week - sources

  Exclusive: AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this week - sources Exclusive: AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this week - sourcesAstraZeneca's large, late-stage U.S. trial has been on hold since Sept. 6, after a participant in the company's UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis.

Pfizer vaccine sees ' encouraging ' results. Another Covid-19 vaccine candidate being developed by US For the initial study , 45 participants ages 18 to 55 were randomly assigned to either receive a certain dose AstraZeneca has been working with the University of Oxford in the UK on the vaccine

AstraZeneca , which is developing AZD1222 vaccine in partnership with Oxford University, has said it is “on track” to roll out up to two billion doses of China has five vaccines in Phase-II human trials – more than any other country. Chinese biopharmaceutical company Sinovac Biotech has said that it is


Video: If you have a cold, you can go back to sick leave by phone (dpa)

It is encouraging that the immune responses in younger and older adults were similar, said an AstraZeneca spokesman. The results confirmed the safety and immune effects of the vaccine. According to the "Financial Times", the results will soon be published in a scientific journal. UK Health Secretary Matt Hancock said the vaccine was not ready but he was preparing the logistics for a possible launch. He expects this in the first half of the coming year.

AstraZeneca is one of the leading companies in the race for a corona vaccine alongside the German biotech company BioNTech with its US partner Pfizer and the US group Moderna. So far there is no vaccine on the international market. Russia became the first country in the world to approve a vaccine in August, but it was tested in humans for less than two months.

A few days ago, AstraZeneca was able to resume the US study with its vaccine after it had been on hold for several weeks due to the illness of a subject. In other countries, the studies were allowed to resume earlier.

COVID-19 vaccine attitudes differ in Australia as experts say we're at a 'precarious time' .
The majority of Australians are ready and willing to take a COVID-19 jab. But as the search for the vaccine ramps up, a survey conducted by the ABC finds others are not as convinced.The IT worker from Brisbane, who left them behind in Jakarta to move to Australia in 2013, has instead resigned herself to daily messages and video calls.

usr: 1
This is interesting!